ECCO2017: European Cancer Congress

My congress planner

Late-Breaking Abstracts


Late-Breaking Abstract Submission

Abstract submission is now CLOSED

Abstract submission deadline: 7 December 2016, 21:00 CET

Late-breaking abstracts describe the latest advances that will change our daily clinical practice. They should highlight novel and practice-changing studies. Focus is placed on capturing abstracts with ground-breaking and unique data that would have been presented for the first time.

Examples of suitable late-breaking abstracts might include the results of a practice-changing prospective Phase III clinical trial; a Phase II study showing anti-tumour activity in a novel context – in each case the results should not have been fully available by the regular abstract submission deadline.

In case of any abstract related queries please contact:

Late-Breaking Abstract Policy & Regulation

Abstracts from Phase III or Phase IV studies for which preliminary data were not available at the time of the regular abstract submission deadline will be considered

Data from the long-term follow-up of previously presented clinical trials may be submitted only if significant new information can be shown.

Interim analysis of a prospective randomized clinical trial will be considered only if it is performed as planned in the original protocol and is statistically valid. If your abstract involves interim analysis, explain the details of your study in the body of the abstract.

The data in the abstract cannot be published (manuscript or abstract) prior to the Congress.

With the submission of a late-breaking abstract to ECCO2017, the presenting author must:

  • Submit by the deadline of 7 December 2016
  • Provide rationale on why the abstract should be considered as late-breaking (complete this section in the submission system).
  • Ensure submission of the abstract adheres to the regular abstract submission policy and regulations in addition to the specific guidelines listed above.
  • Ensure that abstracts contain final results and incorporate statistical analysis. Abstracts submitted stating “results to follow” or similar deferment will not be considered.


Regular and Late-breaking abstracts can only be submitted online through the submission system which will be available on the congress website from 7 November to 7 December 2016.


All late-breaking abstracts will undergo a formal peer-review evaluation by the Executive Scientific Committee and will be judged solely on the data submitted. The final decision on the status of the abstract lies with the Scientific Committee.

Late-breaking abstracts will only be considered for Oral Presentation in Proffered Paper sessions or the Plenary Sessions.  If a late-breaking abstract does not meet the criteria for oral presentation, the abstract will be rejected.

The presenting author will receive confirmation of acceptance or rejection by the end of December 2016.

For questions regarding the submission process, e-mail


ECCO2017 Abstract Submission

Abstract submission is now CLOSED

Abstract submission deadline: 7 December 2016, 21:00 CET

Authors are strongly advised to submit prior to the deadline and avoid unnecessary delays which may affect the standing of their abstract.

The European Cancer Congress is the platform for presenting ground-breaking data to a global audience.  The Congress is highly anticipated by scientific journals, all specialized media and titles of broader public appeal.  A solid media strategy is in place to ensure timely and optimal dissemination of scientific news announced at ECCO2017.  Worldwide scientific media coverage is assured for exciting new data.

Abstracts submitted for presentation in the European Cancer Congress will be reviewed by an international panel of experts in the field of the subject and will be judged solely on the data submitted. The final decision on the presentation format of all selected abstracts is at the sole discretion of the Scientific Committee.

PRINT THIS PAGE Page last modified: